Skip to main content
Trials
Sponsors
Conditions
Drugs
Pricing
Trials
Sponsors
Conditions
Drugs
Pricing
Loading search results
Clinical Trials for "Feng Shen"
6
trials
Share
Relevance
ID
Status
Phase
Title
Sponsor
NCT06902389
Recruiting
Phase 1/2
A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital
ClinicalTrials.gov
NCT06902389
Recruiting
Phase 1/2
A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hep...
Eastern Hepatobiliary Sur...
NCT01717066
Completed
Not Applicable
the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
First Affiliated Hospital of Harbin Medical University
ClinicalTrials.gov
NCT01717066
Completed
Not Applicable
the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperativ...
First Affiliated Hospital...
NCT05453383
Unknown
Phase 2
Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib
Shen Feng
ClinicalTrials.gov
NCT05453383
Unknown
Phase 2
Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Int...
Shen Feng
NCT05779098
Completed
A Machine Learning Architecture to Predict Post-Hepatectomy Liver Failure Using Liver Regeneration Biomarkers and Time-Phased Data
Jinling Hospital, China
ClinicalTrials.gov
NCT05779098
Completed
-
A Machine Learning Architecture to Predict Post-Hepatectomy Liver Failure Using...
Jinling Hospital, China
NCT05781958
Unknown
Phase 2
Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC
Shen Feng
ClinicalTrials.gov
NCT05781958
Unknown
Phase 2
Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advance...
Shen Feng
NCT06699524
Active Not Recruiting
Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid
Shen Feng
ClinicalTrials.gov
NCT06699524
Active Not Recruiting
-
Construction of a Recurrence Risk Prediction Model for Liver Resection Based on...
Shen Feng
Result Breakdown
Status
Completed
2 (33%)
Unknown
2 (33%)
Recruiting
1 (17%)
Active, not recruiting
1 (17%)
Phase
Phase 2
2 (33%)
Not Specified
2 (33%)
Phase 1/2
1 (17%)
not_applicable
1 (17%)
Top Conditions
Advanced Hepatocellular Carcinoma (HCC)
1 (17%)
Stage I Hepatocellular Carcinoma
1 (17%)
Stage II Hepatocellular Carcinoma
1 (17%)
Show 4 more
Top Sponsors
Shen Feng
5 (83%)
Eastern Hepatobiliary Surgery Hospital
1 (17%)
First Affiliated Hospital of Harbin Medical University
1 (17%)
Show 6 more
Start your search
Search over 500,000 clinical trials worldwide
Search
Expert
Popular:
Cancer
Diabetes
Alzheimer
COVID-19
Heart Disease